BBWI

Bath & Body Works Inc

Add to Watchlist

Advanced Chart

30.940

-0.07(-0.226%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

31.390

Open

31.150

VWAP

Vol

4.04M

Mkt Cap

6.55B

Low

30.705

Amount

EV/EBITDA(TTM)

6.27

Total Shares

223.23M

9.80B

EV/OCF(TTM)

9.82

P/S(TTM)

0.92

Bath & Body Works, Inc. is a global omnichannel retailer focused on personal care and home fragrance. The Company offers a range of fragrances for the body and home, including selling collections for 3-wick candles, home fragrance diffusers, fine fragrance mists, liquid hand soaps, body lotions and body creams. It delivers customers their fragrances in multiple forms and categories. The Company sells merchandise through its retail stores in the United States and Canada, and through its Websites and other channels, under the Bath & Body Works, White Barn and other brand names. The Company’s international business is conducted through franchise, license and wholesale partners. It provides in-store experiences at more than 1,890 Company-operated Bath & Body Works locations in the United States and Canada, more than 525 international franchised locations and an online storefront at bathandbodyworks.com. Additionally, it offers a buy online pick-up in-store (BOPIS) option.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q4

FY2026Q3

FY2026Q2

2.85B

+2.38%

2.147

+2.72%

1.64B

+2.01%

0.497

+1.35%

1.55B

+1.71%

0.369

-0.31%

Estimates Revision

The market is revising Upward the revenue expectations for Bath & Body Works, Inc. (BBWI) for FY2026, with the revenue forecasts being adjusted by 0.2% over the past three months. During the same period, the stock price has changed by 1.41%.

Revenue Estimates for FY2026

Revise Upward

+0.2%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-0.84%

In Past 3 Month

Stock Price

Go Up

+1.41%

In Past 3 Month

13 Analyst Rating

32.77% Upside

Wall Street analysts forecast BBWI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBWI is 41.08 USD with a low forecast of 30.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

2 Hold

0 Sell

Strong Buy

32.77% Upside

Current: 30.940

Low

30.00

Averages

41.08

High

50.00

32.77% Upside

Current: 30.940

Low

30.00

Averages

41.08

High

50.00

JPMorgan

Matthew Boss

Overweight

maintain

$40 -> $46

2025-07-28

New

Reason

JPMorgan

Matthew Boss

Price Target

$40 -> $46

2025-07-28

New

maintain

Overweight

Reason

JPMorgan analyst Matthew Boss raised the firm's price target on Bath & Body Works to $46 from $40 and keeps an Overweight rating on the shares. The firm adjusted price targets in the department store and specialty softline group ahead of the Q2 reports. JPMorgan's fieldwork indicates a strong close to the quarter on a July consumer acceleration, the analyst tells investors in a research note.

Barclays

Adrienne Yih

Equal Weight

downgrade

$35 -> $30

2025-05-30

Reason

Barclays

Adrienne Yih

Price Target

$35 -> $30

2025-05-30

downgrade

Equal Weight

Reason

Barclays analyst Adrienne Yih lowered the firm's price target on Bath & Body Works to $30 from $35 and keeps an Equal Weight rating on the shares. The company's Q1 results were in-line with the preliminary results for sales and earnings, the analyst tells investors in a research note. Bath & Body noted that if tariff rates remain unchanged, it would expect its fiscal 2025 results in the lower half of the guidance range, adds Barclays.

BofA

Buy

downgrade

$45 -> $40

2025-05-30

Reason

BofA

Price Target

$45 -> $40

2025-05-30

downgrade

Buy

Reason

BofA lowered the firm's price target on Bath & Body Works to $40 from $45 and keeps a Buy rating on the shares. After the Q1 earnings report, the firm is lowering its FY25 and FY26 EPS estimates by 3% and 4%, respectively, to reflect tariff pressure and a more cautious fiscal year outlook, but adds that it thinks Bath & Body's accelerating sales growth and strong margin profile deserves a higher multiple.

Morgan Stanley

Alex Straton

Overweight

downgrade

$43 -> $41

2025-05-30

Reason

Morgan Stanley

Alex Straton

Price Target

$43 -> $41

2025-05-30

downgrade

Overweight

Reason

Morgan Stanley analyst Alex Straton lowered the firm's price target on Bath & Body Works to $41 from $43 and keeps an Overweight rating on the shares. The firm exits the Q1 report with "a more negative tilt to our Overweight rating," arguing that a negative stock reaction post-earnings is likely a function of Q2 guidance implying quarter-over-quarter sales deceleration, a "noisier" fiscal year guidance reiteration and "less tariff insulation than hoped." While more negative after the report, the firm still thinks Bath & Body is "an attractive relative Overweight" within the Specialty retail space, the analyst added.

Telsey Advisory

Outperform

NULL

downgrade

$43 -> $38

2025-05-30

Reason

Telsey Advisory

Price Target

$43 -> $38

2025-05-30

downgrade

Outperform

NULL

Reason

Telsey Advisory lowered the firm's price target on Bath & Body Works to $38 from $43 and keeps an Outperform rating on the shares. The firm believes the company is building a stronger foundation that will drive incremental growth and profitability in the long term, the analyst tells investors. Telsey reduces its price target on the stock due to continued tariff pressure.

BMO Capital

Simeon Siegel

Outperform

maintain

$50

2025-05-29

Reason

BMO Capital

Simeon Siegel

Price Target

$50

2025-05-29

maintain

Outperform

Reason

BMO Capital analyst Simeon Siegel reiterated an Outperform rating and $50 price target on Bath & Body Works, noting that the shares reversed after rising pre-market. The firm believes the dip was primarily driven by disappointing Q2 trends and guidance, implied second half gross margin compression, and tariff status-quo actualizing at bottom half of guidance. Importantly, management suggested 0%-2% Q2 guidance incorporates a one-timeish roughly 1pt headwind with implied domestic performance above the 0%-2% guide, the analyst tells investors in a research note. The firm added that it understands the "why" but believes the share drop represents a particularly compelling entry point as it continues to believe Bath & Body Works is under-earning and undervalued and sees Q1 as a critical return to growth.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Bath & Body Works Inc (BBWI.N) is 8.64, compared to its 5-year average forward P/E of 12.72. For a more detailed relative valuation and DCF analysis to assess Bath & Body Works Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

12.72

Current PE

8.64

Overvalued PE

15.52

Undervalued PE

9.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

9.35

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

10.85

Undervalued EV/EBITDA

7.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.35

Current PS

0.00

Overvalued PS

1.89

Undervalued PS

0.81